lifestyle.thriveinsider.com

Author: Solid Biosciences Inc.

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 19, 2026
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

March 11, 2026
Solid Biosciences Announces Oversubscribed $240 Million Private Placement

March 6, 2026
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 6, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 2, 2026
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

February 11, 2026
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 11, 2026